Broncoflux

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Broncoflux

Quick Facts

Property Description
Active ingredient Ambroxol hydrochloride
Pharmacological class Mucolytic agent, Secretolytic
Origin Synthetic derivative (Benzylamine structure)
Common form Oral solution, Syrup, Tablet
General purpose Aids in mucus clearance

What Type of Medicine is Broncoflux? (Definition and Classification)

Broncoflux is a pharmaceutical product whose identity is defined by its sole active chemical substance, Ambroxol hydrochloride. It is a single-ingredient product classified primarily as a mucolytic agent and a secretolytic, meaning it works by changing the physical nature of mucus and enhancing its removal. This classification establishes the drug’s core purpose: it is specifically designed to manage conditions involving abnormal mucus secretion within the airways. The efficacy of this classification is clinically recognized for its action on respiratory secretions, which aids the body as an expectorant to relieve the discomfort associated with a congested, productive cough.

Is Broncoflux a Synthetic Drug? (Composition and Origin)

Yes, Broncoflux is a synthetic derivative based on the structure of Ambroxol, which belongs to the class of benzylamine structure derivatives. This synthetic origin ensures a standardized and predictable therapeutic profile. Ambroxol is one of the most widely pharmacologically studied substances in its class for respiratory relief globally. The drug is presented in various pharmaceutical preparations, including oral solution, syrup, tablet, extended-release capsule, nebulization solution, and injection solution, allowing for flexible routes of administration such as oral, inhalation, and parenteral delivery. The Ambroxol component promotes ciliary activity, which is the body’s natural sweeping mechanism in the respiratory tract. This confirms that the drug helps improve the way the airways naturally move mucus out.

General Purpose of a Mucolytic Agent (Therapeutic Focus)

The general purpose of Ambroxol is to promote the reduction of mucus viscosity and enhance the body’s natural mucus clearance process. A typical, neutral use scenario involves managing acute episodes of thick, stubborn mucus accumulation associated with airway irritation. It achieves this by stimulating the serous glandular cells and improving the efficiency of ciliary movement within the airways. This action ensures that the viscous respiratory secretions are thinned and can be effectively swept out, directly addressing congestion and facilitating easier breathing. The core benefit is focused entirely on mobilizing the mucus.

Regulatory References

  1. Ambroxol and bromhexine-containing medicines - referral

What side effects are possible with Broncoflux?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient in Broncoflux organizes potential adverse reactions by the physiological system affected and their reported frequency, as classified in regulatory documents.

Frequency-Classified Adverse Reactions

Frequency Classification Examples of Effects (System-Organ Class)
Common (Affects up to 1 in 10 people) Gastrointestinal: Nausea. Sensory: Taste alteration (Dysgeusia), oral and pharyngeal hypoaesthesia (reduced sensation).
Uncommon (Affects up to 1 in 100 people) Gastrointestinal: Vomiting, Diarrhoea, Dyspepsia (Indigestion), Dry mouth, Upper abdominal pain.
Rare (Affects up to 1 in 1,000 people) Immune/Dermatological: Hypersensitivity reactions, Rash, Urticaria (Hives).
Not Known (Frequency cannot be estimated) Severe Reactions: Anaphylactic reactions, Angioedema, Severe Cutaneous Adverse Reactions (SCARs).

Serious Safety Concerns

The label explicitly documents the risk of Severe Cutaneous Adverse Reactions (SCARs), which are rare but life-threatening hypersensitivity responses. These include conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other serious documented reactions include anaphylactic reactions (e.g., anaphylactic shock) and angioedema (swelling of the face, tongue, or throat).

Population and Condition-Related Safety Constraints

Specific cautions are noted in official prescribing information for individuals with pre-existing conditions. Caution is advised in patients with severe renal or hepatic impairment, as drug clearance may be reduced. Use is also not recommended for individuals with a bronchial motor activity disorder (e.g., ciliary syndrome) due to the risk of massive secretion accumulation and potential airway obstruction. Caution is also advised in patients with a history of peptic ulcer disease.

Overdose and Emergency Response

Overdose Symptoms and When to Seek Help

The documented clinical manifestations of a Broncoflux (Ambroxol hydrochloride) overdose are primarily consistent with an extension of the drug’s known common undesirable effects. Observed short-term presentations typically include diarrhea and restlessness (or anxiety), along with potential nausea and vomiting.

In scenarios of extreme overdosage, regulatory documents indicate that more severe outcomes are possible, including hypotension (low blood pressure) and sialorrhea (excessive saliva secretion). However, serious symptoms have generally not been recorded in clinical experience to date.

Required Emergency Action

If the recommended dosage has been exceeded, it is officially mandated to consult a doctor or seek emergency medical treatment.

The required management approach is to provide care that is mainly symptomatic and supportive. No specific antidote is known for ambroxol overdose, and standard forced elimination methods like dialysis or forced diuresis are considered ineffective due to the compound’s high protein binding. Acute measures, such as gastric lavage, are not generally indicated unless a very high, extreme overdose has occurred.

Population-Specific Overdose Note

For patients with severe renal impairment or severe hepatic impairment, regulatory summaries note that reduced clearance of the drug's metabolites may lead to metabolite accumulation, which must be considered during overdose management.

Therapeutic Uses of Broncoflux

Broncoflux (Ambroxol) is generally used to provide supportive symptomatic relief in conditions involving abnormal mucus secretion and impaired mucus transport in the airways. It is considered relevant for the symptomatic management of acute and chronic bronchopulmonary diseases associated with the formation of viscous, hard-to-separate phlegm. These medicines are widely used as expectorants to help clear mucus. The medication is commonly applied across therapeutic domains where additional symptomatic support is needed to manage symptoms related to physical discomfort caused by retained secretions.

It is considered relevant in conditions like Chronic Bronchitis, certain acute respiratory infections, and Bronchiectasis. Clinical scenarios often involve supporting patients during acute episodes or managing recurrent manifestations in chronic conditions. This application provides support that helps ease the overall symptom burden and offers symptomatic relief that assists with maintaining functional stability.

“This approach is commonly used when symptoms become more noticeable and short-term symptomatic assistance is needed to address the difficulty of coughing up thick phlegm.”


Quick Fact: Relief for Congested Cough

Symptom Domain Therapeutic Focus Practical Benefit
Viscous Phlegm Addresses the viscosity of phlegm May assist in expectoration
Productive Cough Supports mucus transport Contributes to improved breathing comfort
Chest Congestion Assists with secretion movement Helps ease the overall symptom load

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Broncoflux — official regulatory information

The following rules define the officially documented population eligibility for Broncoflux (Ambroxol hydrochloride).


Eligibility scope

Classification Official Regulatory Statement
Populations for whom use is allowed Adults and children over 2 years of age are generally permitted for standard indications.
Populations for whom use is not recommended Use is not recommended during the first trimester of pregnancy and throughout lactation (breastfeeding).
Populations for whom use is contraindicated Patients with known hypersensitivity to ambroxol or its excipients. Use is contraindicated in children under 2 years of age for many oral formulations.
Age-related eligibility rules Contraindicated in children under 2 years. Specific dosage adjustment is not necessary for older adults based on age alone.
Condition-specific eligibility rules Caution is mandated for patients with severe renal impairment or serious hepatic impairment, which may necessitate dose adjustment. Caution is also required in patients with a history of peptic or duodenal ulcers.
Physiological/Clinical Restrictions Use requires caution in patients with compromised airways motility (e.g., primary ciliary dyskinesia).

Eligibility classifications (high-level)

  • Eligibility severity classification: Contraindicated (Absolute Prohibition), Not Recommended (Avoidance/Strong Restriction), and Administered with Caution (Conditional/Supervised Use).
  • Regulatory basis: Eligibility is defined across various national health authority prescribing documents, including the EMA and equivalent national labels.

Connection to the overall eligibility profile:

Regulatory documents strictly define who can and cannot use Broncoflux by establishing clear contraindications for specific populations, such as infants under two years and those with known hypersensitivity. For other sensitive groups, including patients with severe liver or kidney impairment and those who are pregnant or breastfeeding, the official labeling mandates a status of caution or not recommended, which governs eligibility based on explicit clinical status or physiological state. This structured profile is intended to confine usage to populations where eligibility has been established by government authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Broncoflux (Ambroxol hydrochloride), primarily involving a pharmacodynamic restriction and an exposure-enhancing effect with certain drug classes.

Documented Interaction Restrictions

Interaction Type Interacting Substance/Class Official Regulatory Statement
Pharmacodynamic Restriction Cough Suppressants (Antitussives) Co-administration is not recommended due to the risk of airway obstruction from accumulating liquefied sputum, as the cough reflex is suppressed.
Exposure Enhancement Select Antibiotics (Amoxicillin, Cefuroxime, Erythromycin, Doxycycline) Co-administration leads to an increase in the concentration of the antibiotics in bronchopulmonary secretions and sputum.

No clinically relevant unfavorable interactions with other medications have been formally reported in regulatory summaries beyond the noted antitussive restriction and antibiotic enhancement. The drug is not consistently documented as a potent inhibitor or inducer of major metabolic enzymes. The official interaction profile includes constraints related to patient physiology. For individuals with severe hepatic impairment, the clearance of ambroxol is decreased, resulting in plasma levels approximately 1.3 to 2 times higher. Similarly, severe renal impairment is officially noted to cause an expected accumulation of the drug’s hepatic metabolites.

Mechanism of Action

Dual Action Bronchodilation: Targeting Relaxation and Inhibition

Broncoflux achieves its action by simultaneously engaging two critical signaling pathways in the airways: one that initiates muscle relaxation and another that blocks muscle contraction. This dual mechanism provides modulation of bronchial smooth muscle tone, which contributes to reduced airway resistance.


beta2-Adrenergic Receptor Agonism: The Relaxation Cascade

The first component of the mechanism involves binding and activation of beta2-adrenergic receptors on bronchial smooth muscle cells. This interaction activates the cAMP/PKA intracellular signaling cascade. The resulting increase in cAMP levels triggers a molecular sequence that leads to relaxation of the smooth muscle fibers, causing bronchial airway dilation.


Muscarinic M3 Antagonism: Blocking Constriction Signals

The second, complementary mechanism involves the drug acting as a Muscarinic M3 receptor antagonist. By blocking the M3 receptor, the drug prevents the constricting neurotransmitter acetylcholine from binding. This action inhibits the signal transduction sequence that causes muscle contraction, reducing reflex bronchoconstriction and contributing to the modulation of lower airway tone.

Dosage and Administration Information

The official use of Broncoflux (Ambroxol hydrochloride) is governed by specific instructions concerning administration route, dosing schedule, and handling requirements. The medicine is primarily approved for oral administration in the form of tablets, syrups, drops, and extended-release capsules.

Standard Administration Guidelines

Feature Official Dosing and Frequency
Oral Dosing (Adults IR) Initial dose is typically 30 mg three times daily for 2-3 days, followed by a 30 mg twice daily maintenance dose. The maximum daily dose is 120 mg.
Oral Dosing (Adults ER) One 75 mg extended-release capsule is taken once daily.
Intake Condition The medicine can be taken with or without food, although administration after a meal is a common practice. Oral doses must be swallowed with liquid.
Course Duration Use for acute episodes is typically limited to 4 to 5 days without medical consultation. It is also used as part of a long-term therapeutic plan.

Procedural and Population-Specific Instructions

Oral administration requires specific handling: extended-release capsules must be swallowed whole and not chewed or crushed. For liquid forms, proper measurement with an attached device is necessary. If a dose is missed, the protocol is to skip the forgotten dose and continue with the normal schedule; taking a double dose is not permitted. Specific dose adjustments are an official protocol for certain populations. Patients with severe renal or hepatic impairment require either a reduction in the standard dose or an extension of the time interval between doses to account for potential accumulation of the active substance.

Recent Clinical Evidence

Research evidence / Overview of Studies for Broncoflux

Evidence for Use in Acute Respiratory Conditions

Research exploring the use of Broncoflux (Ambroxol) in conditions involving episodic or acute changes in mucus was studied for short-term, randomized controlled trials (RCTs). These studies were designed to measure changes in outcomes related to physical discomfort, such as cough severity and expectoration difficulty. Studies monitored these symptoms in adult and pediatric populations who presented with infections like acute bronchitis and other acute respiratory tract irritations.

Findings contribute to understanding symptom patterns observed in the studies over short treatment periods, typically lasting five to eight days. Research provides insight into short-term changes and often reports how symptoms evolved in the observed populations. What remains uncertain in this acute setting is the full characterization of long-term outcomes that extend past the acute phase of treatment.


Evidence for Use in Chronic Bronchopulmonary Diseases

Research also examined the use of Broncoflux in conditions characterized by fluctuating or episodic manifestations, such as Chronic Bronchitis and COPD. The evidence for this purpose involves systematic reviews and longer-duration randomized trials, which track disease patterns over months. These studies monitored outcomes reflecting daily functioning or activity level, such as the frequency of acute exacerbations (flare-ups) and measures of health-related Quality of Life (QoL).

Trials reported measurements tracking the number of exacerbation events and the resulting hospitalization rates for the studied groups. However, findings were mixed or hard to interpret due to the inclusion of various similar mucolytic agents across different trials.


Evidence in Specific Patient Populations

Research has evaluated Broncoflux in both adult and pediatric patients. For children, research was studied for its use in research contexts involving acute and chronic bronchopulmonary disorders. Official regulatory bodies have noted that data for certain groups remain insufficient, meaning there is limited information for its use in children below 6 years of age. Research in these very young populations is still emerging, and evidence quality varies for this subgroup.

Key Studies & References Public Assessment Report Scientific discussion Rivendra Ambroxol hydrochloride DK/H/2363/001-002/DC (Regulatory Efficacy Summary for Chronic and Acute Use)

Frequently Asked Questions (FAQ)

Common questions about Broncoflux (FAQ)

Q: What kind of cough is Broncoflux best used for?

A: Broncoflux is a mucolytic agent used primarily for conditions associated with abnormal mucus secretion and a productive cough. Official product information indicates that it is intended to aid the clearance of thick mucus (phlegm) from the airways.

Q: How long does the cough relief from Broncoflux typically last?

A: Regulatory documents indicate that the action of the medicine typically begins after 30 minutes following an oral dose. The effect is generally reported to persist for 6 to 12 hours, though individual experiences may vary.

Q: Can Broncoflux be used for common cold symptoms other than cough?

A: The medicine may be used for respiratory disorders like the common cold and bronchitis, but only when these conditions are accompanied by the problem of excessive mucus (phlegm). Its main role is always focused on managing secretions.

Q: Does Broncoflux contain any alcohol or sugar?

A: The liquid forms of Broncoflux, such as syrups or oral solutions, often contain excipients like sorbitol, which is a sugar substitute. The label includes a warning that patients with conditions such as hereditary fructose intolerance are advised to consult a healthcare professional regarding sorbitol-containing products. Official labels do not consistently warn about alcohol content.

Q: Can Broncoflux cause drowsiness or affect my energy level?

A: Regulatory safety information lists drowsiness (somnolence) as an adverse reaction, though its frequency is classified as not known. Official product labels state the drug may have a minor influence on activities requiring alertness, such as operating machinery or driving.

Q: Is it safe to take Broncoflux at the same time as cold and flu tablets?

A: Official warnings state that taking Broncoflux with cough suppressants (antitussives) is not recommended. This combination carries a risk of secretion accumulation and airway obstruction, as the cough reflex is blocked while the medicine is helping to liquefy and increase mucus.

Q: Can people with high blood pressure safely use Broncoflux?

A: While the active ingredient alone is not specifically contraindicated for high blood pressure, some official warnings advise caution for patients with serious cardiovascular disorders. In some contexts, caution is advised for patients with serious cardiovascular disorders, especially when the product includes ingredients like beta-agonists.

Q: Is Broncoflux suitable for individuals with asthma or COPD?

A: The medicine may be indicated for long-term respiratory conditions, including COPD and chronic inflammatory pulmonary conditions. However, official warnings state that caution is advised for individuals with asthma, particularly during acute asthmatic attacks.

Q: Are there long-term side effects associated with continuous use of Broncoflux?

A: Clinical trials involving long-term treatments (up to two years) have reported that the active ingredient was generally well-tolerated. Official safety information classifies adverse effects based on frequency, but not typically by duration of use (long-term versus short-term).

Q: Is Broncoflux used for dry cough, wet cough, or both?

A: Official therapeutic indications focus on the secretolytic therapy of acute and chronic disorders that are associated with pathologically thickened mucus. This means the medicine is primarily used for a wet (productive) cough where mucus needs to be expelled.

Q: Is there any evidence about Broncoflux causing interactions with herbal supplements?

A: Official drug labels commonly include a general warning to patients. They advise informing a healthcare professional about all current medicines, including herbal products and dietary supplements, before starting treatment, as potential interactions should be assessed.

Q: Why is Broncoflux sometimes used for conditions like sinusitis or ear infections?

A: Beyond respiratory tract indications, studies have explored the use of the drug in conditions like secretory otitis media (a type of ear infection). This potential use is due to its properties of improving ciliary movement and aiding the discharge of accumulated secretions.

Q: Is there a maximum number of days Broncoflux should be used consecutively?

A: Official regulatory documents specify that for acute episodes, the syrup form is typically limited to 4 to 5 days of use without consulting a healthcare professional. For chronic conditions, long-term use is possible only under professional supervision.

Q: Can Broncoflux interact with common medications for heartburn or acid reflux?

A: The official label does not typically specify drug-drug interactions with acid reflux medications, but it does list heartburn as a rare side effect of Broncoflux itself. While no specific drug-drug interaction with acid reflux medication is typically listed, the use still requires caution for patients with a history of peptic ulcer disease.

Q: Can taking Broncoflux cause headaches?

A: According to official regulatory summaries on adverse reactions, a headache is listed as a rare side effect. This means it affects up to 1 in 1,000 people who use the medicine.

Q: What are the possible signs of a serious, though rare, allergic reaction to Broncoflux?

A: Serious allergic reactions, such as anaphylaxis or angioedema, are rare but documented events. Signs can include hives, rash, swelling of the face, lips, tongue, or eyes, and difficulty breathing. If these signs are observed, it is recommended to seek prompt medical attention.

Q: How quickly should I expect to feel the effects of Broncoflux?

A: Official product information on the pharmacodynamic properties confirms that the onset of action following oral administration typically commences after 30 minutes.

Q: Is a metallic or strange taste in the mouth an expected side effect of Broncoflux?

A: Yes, an altered sense of taste, medically termed dysgeusia, is listed as a common side effect in regulatory documents. This means it affects up to 1 in 10 people who use the product.

Q: Is it normal for a cough to feel 'looser' after starting Broncoflux?

A: Yes, this feeling is consistent with how the medicine works. Regulatory documents state the drug promotes the reduction of mucus viscosity (it thins the mucus) and enhances mucus clearance, which is designed to facilitate easier expectoration.

Q: What does 'expectoration' mean in the context of how Broncoflux works?

A: In the context of respiratory medicine, expectoration means the natural process of coughing up and expelling mucus or phlegm from the lungs and throat. Broncoflux makes this process easier by thinning the thick respiratory secretions.

Q: Is Broncoflux known to have different formulations in different countries?

A: Official regulatory documents and product labels from various global markets confirm that the drug is available in multiple forms. These formulations include tablets, syrups, extended-release capsules, and oral drops, confirming variations in the product type across different regions.

Q: Why might doctors recommend a mucolytic for chronic bronchitis?

A: Broncoflux is formally indicated for the secretory therapy of chronic bronchopulmonary diseases like chronic bronchitis. This is because it helps manage the thick, problematic mucus associated with these long-term conditions and may help to reduce the frequency of acute flare-ups (exacerbations).

How should Broncoflux be stored and disposed of?

How to Store and Dispose of Broncoflux?

Storage and disposal of Broncoflux (Ambroxol) must strictly adhere to the conditions specified in the official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30°C or below 25°C (depending on the formulation).
Protection Keep protected from light and moisture. Liquid forms should generally not be frozen.
Safety Keep out of the sight and reach of children.
Container Store in the original container and keep it tightly closed.

Disposal Instructions

Unused or expired Broncoflux should not be disposed of via wastewater or household waste. Disposal must be done in accordance with local regulations, often through community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Broncoflux found in:

A-Z Index: